Thank you to the whole team who worked on our Covid-19 project! biorxiv.org/content/10.110…

Excited to share our work on “VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite”. Great teamwork by Shao’s lab, Zhu Lab, and wilson’s lab Scripps Research . advances.sciencemag.org/content/6/38/e…

Nanoparticle vaccine for COVID-19 spurs robust immune response in preclinical tests. scripps.edu/news-and-event…

A big congratulations to Dr. Yinan Zhang Yi-Nan Zhang from our lab, for receiving a Postdoctoral Fellowship from the NSERC of Canada. Dr. Zhang's research aims to develop rational strategies to incorporate antigen and adjuvant components for vaccines. #scrippsresearch

Congratulations to the Zhu Lab Zhu Lab for the COVID-19 vaccine paper in Science Advances! Scripps Research #SARSCov2 scripps.edu/news-and-event… advances.sciencemag.org/content/7/12/e…

Congratulations to Yinan and the whole team on the submission of a new manuscript on the COVID-19 vaccine mechanism! Here is the link: biorxiv.org/content/10.110…

Thank you to Dr. Yinan Zhang and everyone in Zhu Lab for your contribution to our #COVID research scripps.edu/news-and-event… #COVID.

Scientists in Prof. Jiang Zhu’s lab unveil a new #ebola #vaccine strategy which may provide a better immune response than current approaches and greater stability from the #nanoparticle design. scripps.edu/news-and-event… Nature Communications Zhu Lab

Zhu Lab is pleased to announce our new #Ebola vaccine paper - "Single-component multilayered self-assembling nanoparticles presenting rationally designed glycoprotein trimers as Ebola virus vaccines" Thank you to all who worked so hard on this project. doi.org/10.1038/s41467…

Scripps Research "News and Events" highlights the Zhu Lab research into a new Ebola Virus vaccine design. scripps.edu/news-and-event… #ebola

Thank you to the TSRI Zhu Lab members and Dr. Yi Zhang from HMH for your assistance with our research, published this week in Science Advances. science.org/doi/10.1126/sc…

Our HIV-1 vaccine manuscript is now available from bioRxiv: biorxiv.org/content/10.110…. Two of the nanoparticle vaccine candidates from this manuscript are advancing to human trials in 2023.

A new #HIV vaccine developed by Zhu Lab has shown a significantly improved ability to neutralize the virus in preclinical tests. The nanoparticle-based vaccine will soon be studied in healthy people who volunteer to participate in clinical trials scripps.edu/news-and-event…

Great news! Our lab's latest research on #influenza is now available on bioRxiv. Dive into our innovative approach in developing a pan-influenza A vaccine here: biorxiv.org/content/10.110… #InfluenzaResearch #VaccineDevelopment #FluVaccine

Our World Chemistry Congress celebrated cross-collaborations. Similarly, our latest IUPAC Top Ten list highlights innovation across different disciplines, towards clean energy, fuels, food and pharmaceuticals for all. Follow #IUPACTop2023 to learn more: buff.ly/409Kt4x

Congratulations to the Zhu lab to be listed in IUPAC’s 2023 Top Ten Emerging Technologies in Chemistry! iupac.org/iupac-2023-top… IUPAC The Ward Lab

Check out the latest publication released on BioRxiv: A tale of two fusion proteins: understanding the metastability of human respiratory syncytial virus and metapneumovirus and implications for rational design of uncleaved prefusion-closed trimers biorxiv.org/content/10.110…

Our RSV and hMPV vaccines' paper "Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus" was published. 😀Congrats to Zhu lab team Zhu Lab, Scripps Research. nature.com/articles/s4146…